These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 28590316

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.
    BMC Ophthalmol; 2016 Jul 27; 16():127. PubMed ID: 27465105
    [Abstract] [Full Text] [Related]

  • 4. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM, Ouchi C, Shiode Y, Kimura S, Matoba R, Morita T, Morizane Y.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct 27; 262(10):3099-3107. PubMed ID: 38625447
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H.
    Jpn J Ophthalmol; 2018 Mar 27; 62(2):144-150. PubMed ID: 29411171
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M, Giustolisi R, Marchiori J, Bruscolini A, Mallone F, Fameli V, Nebbioso M, Abdolrahimzadeh S.
    Curr Eye Res; 2018 Mar 27; 43(3):391-396. PubMed ID: 29166140
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC, Du W, Gibson A, Saroj N.
    Ophthalmol Retina; 2021 Feb 27; 5(2):141-150. PubMed ID: 32652314
    [Abstract] [Full Text] [Related]

  • 9. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar 27; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC, Lee DK, Kim SH, You YS, Kwon OW.
    Korean J Ophthalmol; 2015 Aug 27; 29(4):226-32. PubMed ID: 26240506
    [Abstract] [Full Text] [Related]

  • 12. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK, Faber RT, Moe MC.
    Acta Ophthalmol; 2017 Aug 27; 95(5):460-463. PubMed ID: 28556485
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT study group.
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar 27; 255(3):493-502. PubMed ID: 27628062
    [Abstract] [Full Text] [Related]

  • 14. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
    Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H.
    Acta Ophthalmol; 2018 May 27; 96(3):e393-e398. PubMed ID: 29220114
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D.
    Retina; 2018 Jul 27; 38(7):1276-1288. PubMed ID: 28723848
    [Abstract] [Full Text] [Related]

  • 17. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct 27; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.